公司資料
Entrada Therapeutics 股價、新聞與催化劑
- 股票代碼:
- TRDA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
7.57 USD (-0.39%)
收盤價
最後更新: 2026年8月21日
258M USD
市值
股價為何變動
As of Aug 21, 2026, TRDA closed down 0.39% at $7.57. No new same-company headline was identified in the current news window.
公司概覽
Intracellular Genetic Medicines
Entrada Therapeutics develops Endosomal Escape Vehicle therapeutics intended to deliver oligonucleotides into cells and engage previously inaccessible intracellular targets.
ENTR-601-44
ENTR-601-44 is an exon-skipping candidate for people with Duchenne muscular dystrophy amenable to exon 44 skipping.
ENTR-601-45
ENTR-601-45 applies the same intracellular-delivery platform to patients amenable to exon 45 skipping.
ELEVATE Clinical Program
The ELEVATE studies evaluate multiple ascending doses, safety, target engagement and early functional outcomes to guide further development of Entrada's Duchenne franchise.
未來催化劑
- ELEVATE-45-201 Cohort 1 data around mid-2026.
- ELEVATE-44-201 open-label-period and Cohort 2 data by year-end 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。